United States Patent 6,617,317: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
The United States Patent 6,617,317, titled "Boronic Ester and Acid Compositions," was granted on September 9, 2003, to Millennium Pharmaceuticals, Inc. This patent is significant in the field of pharmaceuticals, particularly in the synthesis and use of boronic ester and acid compounds. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Inventors and Assignee
The patent was invented by Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, and Louis Plamondon, all affiliated with Millennium Pharmaceuticals, Inc., based in Cambridge, MA[2].
Background and Prior Art
The patent builds upon a series of earlier applications and patents, starting from 1994. It is a continuation of several previous applications, including those filed in 1995, 1998, 2000, and 2001. This indicates a long-standing research and development effort in the area of boronic ester and acid compositions[2].
Scope of the Patent
The patent covers novel boronic ester and acid compounds, their synthesis, and their uses. Specifically, it addresses the stabilization and protection of proteins in animals by using these compounds. The scope includes various chemical structures and methods for preparing these compounds, as well as their applications in pharmaceutical and biomedical fields[2].
Chemical Structures
The patent describes a range of boronic ester and acid compounds, including those with aryl, alkyl, cycloalkyl, and other substituent groups. It also details the use of halogens, sulfur, and other functional groups in these compounds[1][2].
Synthesis Methods
The invention includes detailed methods for synthesizing these boronic ester and acid compounds. These methods involve various chemical reactions and conditions to produce the desired compounds with high purity and yield[2].
Applications
A key application of these compounds is in reducing the rate of degradation of proteins in animals. This is crucial in the development of therapeutic proteins and enzymes, where stability and efficacy are paramount. The patent also hints at potential uses in other biomedical applications, such as drug delivery and diagnostics[1][2].
Claims
The patent includes 22 claims that define the scope of the invention. Here are some key claims:
Claim 1
This claim describes a method for reducing the rate of degradation of proteins in an animal by contacting cells of the animal with certain boronic ester and acid compositions[1].
Claim 2-5
These claims detail the specific chemical structures of the boronic ester and acid compounds, including the types of substituent groups and functional groups used[1].
Claim 6-10
These claims cover the methods for synthesizing the boronic ester and acid compounds, including the reactants, conditions, and steps involved in the synthesis process[1].
Claim 11-22
These claims address the various applications of the compounds, including their use in stabilizing proteins, drug delivery systems, and other biomedical applications[1].
Patent Landscape
Related Patents
The patent is part of a larger family of patents related to boronic ester and acid compositions. It is connected to earlier patents such as US 5,780,454 and US 6,465,433, which also deal with similar compounds and their applications[2].
Global Patent Family
Using tools like the Global Dossier, one can see that this patent is part of a global patent family with related applications filed in other IP offices. This indicates a broad international interest in these compounds and their applications[4].
Citation Data
The Common Citation Document (CCD) can provide insights into the prior art cited by various IP offices for this patent family. This helps in understanding the global context and the state of the art in this field[4].
Economic and Research Implications
Patent Scope Measurements
The USPTO's Patent Claims Research Dataset can be used to analyze the scope and claims of this patent in comparison to other patents in the field. This dataset provides detailed information on claims from US patents and applications, helping researchers understand the breadth and depth of the invention[3].
Industry Impact
The development and patenting of boronic ester and acid compositions have significant implications for the pharmaceutical and biomedical industries. These compounds can enhance the stability and efficacy of therapeutic proteins, which is a critical area of research and development.
Key Takeaways
- Novel Compounds: The patent introduces novel boronic ester and acid compounds with specific chemical structures.
- Synthesis Methods: Detailed methods for synthesizing these compounds are provided.
- Applications: The compounds are used to stabilize proteins and have potential in various biomedical applications.
- Patent Family: The patent is part of a larger family of related patents and international applications.
- Economic Impact: The invention has significant implications for the pharmaceutical and biomedical industries.
FAQs
Q: What is the main purpose of the boronic ester and acid compositions described in US Patent 6,617,317?
A: The main purpose is to reduce the rate of degradation of proteins in animals, thereby stabilizing therapeutic proteins and enzymes.
Q: Who are the inventors of this patent?
A: The inventors are Julian Adams, Yu-Ting Ma, Ross Stein, Matthew Baevsky, Louis Grenier, and Louis Plamondon.
Q: What is the assignee of this patent?
A: The assignee is Millennium Pharmaceuticals, Inc.
Q: How many claims are included in this patent?
A: There are 22 claims that define the scope of the invention.
Q: What tools can be used to analyze the global patent family of this invention?
A: Tools such as the Global Dossier and the Common Citation Document (CCD) can be used to analyze the global patent family and citation data.
Sources
- US6617317B1 - Boronic ester and acid compositions - Google Patents
- (12) United States Patent - googleapis.com
- Patent Claims Research Dataset - USPTO
- Search for patents - USPTO
